Press coverage about Eiger Biopharmaceuticals (NASDAQ:EIGR) has been trending somewhat positive on Monday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.810569382563 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Monday, October 16th. Oppenheimer set a $34.00 price objective on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, December 7th. Piper Jaffray Companies restated an “overweight” rating and set a $17.00 price objective (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, Ladenburg Thalmann Financial Services assumed coverage on shares of Eiger Biopharmaceuticals in a research report on Wednesday, January 3rd. They set a “buy” rating and a $32.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $27.25.

Eiger Biopharmaceuticals (EIGR) traded up $0.50 during midday trading on Monday, hitting $8.65. 86,116 shares of the stock traded hands, compared to its average volume of 257,538. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19. Eiger Biopharmaceuticals has a twelve month low of $6.10 and a twelve month high of $16.20. The stock has a market capitalization of $88.34, a price-to-earnings ratio of -1.63 and a beta of 1.91.

ILLEGAL ACTIVITY WARNING: “Eiger Biopharmaceuticals (EIGR) Getting Somewhat Favorable Media Coverage, Report Shows” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with's FREE daily email newsletter.